While CD8+/CD3+/CD45RO+ TILs seem to be pivotal for the establishment of a TNM-I for NSCLC SCC patients, CD66b+ TANs may prove an appropriate choice for ADC patients. This evidence concerns the gene CEACAM8 and non-small cell lung carcinoma.